3H Biomedical is an innovative life-science company that discovers, develops and distributes human cell-based products and technologies for life science research, drug development and tissue engineering. We take pride in our contribution to improving human health and environment. Our mission is to help scientists be more productive, more competitive and more innovative. Serving the global research community, biotech sector and pharmaceutical industry. We supply more than 260 different types of primary human cells, media and cell-based products. R&D projects: EUROSTARS: PREVAIL Preclinical development of novel ERRalpha inhibitors for treatment of Triple Negative Breast Cancer. The PREVAIL project will deliver a first-in-class targeted therapeutic for treatment of triple negative breast cancer (TNBC). SEAL OF EXCELLENCE Next generation of targeted dendritc cell vaccine for cancer treatment, a therapeutic cancer vaccine technology platform. We are actively seeking partners in the pharmaceutical industry and clinical centres in order to co-develop our patented vaccine technology.
Looking for a particular 3H Biomedical AB employee's phone or email?
3H Biomedical AB Questions
The 3H Biomedical AB annual revenue was $6.8 million in 2026.
Mallen Huang is the CEO of 3H Biomedical AB.
2 people are employed at 3H Biomedical AB.
3H Biomedical AB is based in Uppsala, Uppsala Lan.
The NAICS codes for 3H Biomedical AB are [32541, 325414, 325, 3254, 32].
The SIC codes for 3H Biomedical AB are [283, 28].
Top 3H Biomedical AB Employees
-
Mallen Huang
CEO at 3H Biomedical AB
Uppsala, Uppsala County, SE11 -
Anders Gobl
Owner at 3H Biomedical AB
Uppsala, Uppsala County, SE15
Related Companies
